CD226 Throttles up CD8+ T Cell Antitumor Activity
- PMID: 33053327
- DOI: 10.1016/j.immuni.2020.09.013
CD226 Throttles up CD8+ T Cell Antitumor Activity
Abstract
In this issue of Immunity, Weulersse et al. and Braun et al. explain how CD226 expression loss on CD8+ T cells impairs TCR-driven activation, and thereby anti-tumor effector responses, tantamount to taking the CD8+ T cell's foot off the gas pedal.
Copyright © 2020 Elsevier Inc. All rights reserved.
Comment on
-
CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.Immunity. 2020 Oct 13;53(4):805-823.e15. doi: 10.1016/j.immuni.2020.09.010. Immunity. 2020. PMID: 33053330
-
Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.Immunity. 2020 Oct 13;53(4):824-839.e10. doi: 10.1016/j.immuni.2020.09.006. Immunity. 2020. PMID: 33053331
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources